Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
07 mars 2024 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended...
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
06 mars 2024 08h00 HE
|
Vaxart, Inc.
Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”)...
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
05 févr. 2024 08h00 HE
|
Vaxart, Inc.
— Data served as foundation for current vaccine candidate for planned Phase 2 research — Vaxart vaccine candidates elicited strong antigen-specific serum IgG and IgA with neutralizing activity...
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
19 janv. 2024 08h30 HE
|
Vaxart, Inc.
- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator - - Project NextGen is a $5 billion initiative by...
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
16 janv. 2024 09h25 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for...
Vaxart, Inc. Announces Management Change
16 janv. 2024 09h22 HE
|
Vaxart, Inc.
Chief Executive Officer Andrei Floroiu Resigns Chair Michael J. Finney, Ph.D. to Serve as Interim Chief Executive Officer SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart,...
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
21 déc. 2023 08h00 HE
|
Vaxart, Inc.
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and...
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
02 nov. 2023 16h01 HE
|
Vaxart, Inc.
Norovirus challenge study topline results indicate the potential of Vaxart’s oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding ...
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
02 nov. 2023 08h00 HE
|
Vaxart, Inc.
Trial evaluating the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) --...
Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2
26 oct. 2023 08h00 HE
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...